CMPX
HEALTHCARECompass Therapeutics Inc
$1.87-0.08 (-4.10%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CMPX Today?
No stock-specific AI insight has been generated for CMPX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.61$6.88
$1.87
Fundamentals
Market Cap$337M
P/E Ratio—
EPS$-0.40
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume11.5M
Avg Volume (10D)—
Shares Outstanding180.1M
CMPX News
21 articles- Canaccord Maintains Buy Rating on Compass Therapeutics (CMPX)Yahoo Finance·May 5, 2026
- Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate UpdateYahoo Finance·May 5, 2026
- Does Compass Therapeutics' (CMPX) Biliary Cancer Data Hint At A Broader Pipeline Re‑Rating Opportunity?Yahoo Finance·Apr 29, 2026
- Micron initiated, Rambus downgraded: Wall Street's top analyst callsYahoo Finance·Apr 28, 2026
- Compass Therapeutics’s stock crashes after OS miss in BTC trialClinicaltrialsarena·Apr 28, 2026
- Midday Fly By: Verizon reports ‘beat and raise,’ Shell to acquire ARCYahoo Finance·Apr 28, 2026
- Compass Therapeutics Touts “Stunning” PFS Win in COMPANION-002 as Crossover Muddy OS DataMarketbeat·Apr 27, 2026
- This Biotech Stock Is Down 65%. How a Cancer Trial Was Ruined by Its Own Design.Yahoo Finance·Apr 27, 2026
- Compass Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesGlobeNewswire Inc.·Apr 27, 2026
- Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract CancerYahoo Finance·Apr 27, 2026
- Compass Therapeutics, Inc.'s (NASDAQ:CMPX) Path To ProfitabilityYahoo Finance·Apr 26, 2026
- Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract CancerGlobeNewswire Inc.·Apr 24, 2026
- Compass Therapeutics, Inc. (CMPX) Up 200% Year-on-YearYahoo Finance·Apr 21, 2026
- Will Psychedelic Stocks Have A Trippy Ride Under RFK Jr.?Yahoo Finance·Apr 2, 2026
- What Compass Therapeutics (CMPX)'s Pipeline Progress And 2025 Losses Reveal About Its Oncology StrategyYahoo Finance·Mar 9, 2026
- Compass Therapeutics Reports 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 5, 2026
- Assessing Compass Therapeutics (CMPX) Valuation As CTX-009 Gains Attention In Biliary Tract Cancer MarketYahoo Finance·Mar 3, 2026
- Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsightYahoo Finance·Mar 2, 2026
- Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC FilingMotley Fool·Mar 2, 2026
- Is Compass Therapeutics, Inc. (CMPX) Outperforming Other Medical Stocks This Year?Yahoo Finance·Feb 17, 2026
- Wall Street Analysts See an 113.73% Upside in Compass Therapeutics, Inc. (CMPX): Can the Stock Really Move This High?Yahoo Finance·Jan 27, 2026
All 21 articles loaded
Price Data
Open$1.90
Previous Close$1.95
Day High$1.93
Day Low$1.84
52 Week High$6.88
52 Week Low$1.61
52-Week Range
$1.61$6.88
$1.87
Fundamentals
Market Cap$337M
P/E Ratio—
EPS$-0.40
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume11.5M
Avg Volume (10D)—
Shares Outstanding180.1M
About Compass Therapeutics Inc
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple human diseases. The company is headquartered in Boston, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—